Wissam Abouzgheib is a Respiratory physician affiliated with Cooper University Hospital. OpenAlex indexes 80 publications with 870 citations (h-index 16); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
3 Cooper Plz Rm 104
Camden, NJ 081031407
Telephone
856-968-8695Provider last certified this registry record 13 Jun 2022.
Clinical trials
- Talc Outpatient Pleurodesis With Indwelling Catheter
Sponsor: The Cooper Health System
- Use of Dexmedetomidine for Sedation During Flexible Bronchoscopy in Patients With COPD: A Descriptive Study
Sponsor: The Cooper Health System
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
8 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Boston Scientific CorporationProgram year202415 payments$10,113openpaymentsdata.cms.gov ↗
- INTUITIVE SURGICAL, INC.Program year20244 payments
- Olympus Medical Systems CorporationProgram year20248 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Respiratory
100%Anticholinergic37.5%Incruse Ellipta100%Part D<11 patientsbeta2-Adrenergic Agonist32.5%Albuterol Sulfate Hfa100%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Unlocking the potential of robotic-assisted bronchoscopy: overcoming challenging anatomy and locations
Therapeutic Advances in Respiratory Disease
2024 - A multicenter observational study assessing the safety, feasibility, and complications of Bonastent in central airway obstruction
Therapeutic Advances in Respiratory Disease
2024 - Oxygen insufflation through the bronchoscope channel for sedation-induced hypoxia: safe and effective
Therapeutic Advances in Respiratory Disease
2023 - Cryotherapy: A Safe Approach to Pulmonary Hemorrhage During VV-ECMO
Journal of Investigative Medicine High Impact Case Reports
2022 - Therapeutic closure of bronchopleural fistulas using ethanol
Therapeutic Advances in Respiratory Disease
2021
Similar KOLs
Other experts from the same institution or the same specialty.
Tudor Jovin, MD
Cooper University Hospital
Fred Rincon, MD
Cooper University Hospital
Naomi Lawrence, MD
Cooper University Hospital
Anthony Dragun, MD
Cooper University Hospital
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”